Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 22468 matches for

"While I am excited to be a part of this super team, our paper is a sobering reminder that we need to strengthen our systems to ensure newborns everywhere receive high-quality healthcare." Adeniyi Aderoba (cohort 2018-19)

adeniyi aderoba
Photograph of Adeniyi Aderoba

FD-TACT malaria treatment trial launches patient recruitment in Rwanda

A Phase 3 pivotal trial, led by MORU and funded by Japan’s Global Health Innovative Technology Fund (GHIT), has begun to evaluate a novel fixed-dose triple artemisinin-based combination treatment (FD-TACT) for uncomplicated Plasmodium falciparum malaria.

Professor Edwine Barasa Appointed as Executive Director of the KEMRI-Wellcome Research Programme

Professor Edwine Barasa has been appointed as the Executive Director of the KEMRI-Wellcome Research Programme (KWRP), following the completion of a highly competitive recruitment process conducted by the Programme’s partners: the University of Oxford, KEMRI and Wellcome.

OUCRU workshop drives dialogue on early warning systems for climate-sensitive infectious diseases

Researchers, policymakers, and health professionals gathered at the Oxford University Clinical Research Unit (OUCRU) for a workshop on “Enablers and Barriers to Development and Implementation of Early Warning and Response Systems for Climate-Sensitive Infectious Diseases in Viet Nam.”

From Evidence to Impact: Transforming Sickle Cell Care in Kenya

Sickle cell anaemia is a genetic condition causing red blood cells to become sickle-shaped, leading to painful complications and other health issues. In Kenya, it is common in malaria-prone regions, where the sickle cell trait offers some protection. Ongoing research and a long-standing clinic in Kilifi have improved survival rates, with more adults living full lives. Collaboration with local health authorities and the Ministry of Health supports early diagnosis, care guidelines, and expanded regional services.

Kevin Marsh awarded RSTMH’s 2025 Sir Patrick Manson Medal

The Royal Society of Tropical Medicine and Hygiene's most prestigious award, the Sir Patrick Manson Medal, is being given this year to Professor Kevin Marsh, a Malariologist and Global Health Researcher. Professor Marsh is the Director of the Africa Oxford Initiative and Senior Adviser Science for Africa Foundation at the University of Oxford. His major research interests focus on immunity to and pathogenesis of malaria, and he has a particular interest in supporting science and scientific leadership across Africa.

New partnership aims to tackle antibiotic overuse in African children’s hospitals

PediSEP-1, a new study funded by the EDCTP3 Horizon programme, has launched to combat antimicrobial resistance (AMR) in African hospitals. The initiative introduces a risk-differentiated care approach identifying low-risk children who can be safely discharged early with minimal or no antibiotics supported by targeted parental education and ‘virtual ward’ follow up by phone. The project seeks to reduce antibiotic overuse and AMR transmission, and increase system efficiency

Building Vietnam’s Clinical Trial Future: OUCRU and Partners at the Forefront

On 26 September 2025, leading researchers, policymakers, and international partners gathered in Hanoi for the Workshop on Clinical Trial Opportunities in Viet Nam, co-organised by the World Health Organization, Hanoi Medical University, and the Oxford University Clinical Research Unit (OUCRU). The event marked an important step in strengthening Vietnam’s clinical trial ecosystem, aligning national ambitions with global health innovation.

MORU Community Advisory Boards meet in Bangkok

From 21-22 Aug, twenty five MORU Major International Programme (MIP) colleagues attended the second CAB-NET meeting in Bangkok and online. Run by MORU Bioethics & Engagement (B&E), CAB-NET is a network that bring together the facilitators of community advisory boards (CABs) run by the MORU MIP to share activity updates, ideas and best practices, training, and network.

Joel Tarning awarded RSTMH’s 2025 Chalmers Medal

Professor Joel Tarning, head of MORU’s Clinical Pharmacology Department, has been honoured with the award of the Royal Society of Tropical Medicine and Hygiene’s Chalmers Medal for his exceptional contribution to the field of clinical pharmacology of neglected tropical diseases, and in particular antimalarial therapy.

A migrant mother’s 4-hr walk for antenatal care

On the Thai-Myanmar border, life is often a daily struggle, especially for expectant mothers like migrant day labourer Daw Mu (name changed for privacy), who lives in a village near Jaydi Koh in Tak Province’s Phop Phra District. Now three months pregnant with her second child, Daw Mu must walk 4 hours to the Jaydi Koh SMRU/BHF outreach clinic for antenatal care, often with her four-year-old son by her side.

MODRA Cohort 2 begins: Empowering the next generation of leaders in global health

Fifteen emerging scientists from South and Southeast Asia begin an 18-month journey with MODRA. Together, they are gaining the skills to lead research that makes a difference in global health.

New study find treatment for Chagas disease is excessive

A new study has found the current recommended treatment for Chagas disease could be given over a substantially shorter time period and still be as effective.

Bridging science and practice to improve the outcome of patients with dengue

Dengue cases in Ho Chi Minh City surged by 170% in 2025, straining hospitals and affecting both children and adults. In response, OUCRU and partners held a workshop with over 200 health professionals to share research, identify clinical gaps, and advance collaborative efforts for improved dengue diagnosis and treatment.

OUCRU researchers have a leading role in developing first International Clinical Practice Guideline for Tuberculous Meningitis

OUCRU researchers have played a leading role in developing the world’s first international clinical practice guideline for tuberculous meningitis (TBM), now published in The Lancet Infectious Diseases.

New study maps immune cells fuelling harmful inflammation in tuberculous meningitis

Tuberculous meningitis (TMB) harms not only through infection, but also through the body’s own overactive immune response. Using single-cell RNA sequencing, OUCRU scientists have identified specific immune cells in the brain that may be driving this harmful inflammation. Their study established a cutting-edge cellular method to identify new therapeutic targets for host-directed therapy, aimed at improving survival and reducing immune-mediated brain injury in TBM patients.

OUCRU release report on intensive care training programme in Vietnam

After more than three years of collaboration, OUCRU and Dragon Capital are pleased to announce the release of the final report of the Intensive Care Training Programme for Life-Threatening Infectious Diseases in Vietnam.

Tracking resistance: Mapping the spread of drug-resistant malaria

On World Mosquito Day, Dr Lucy Harrison, postdoctoral researcher at Oxford’s Infectious Diseases Data Observatory (IDDO) at the Centre for Tropical Medicine and Global Health, reflects on the global impact of the mosquito and her research into malaria drug resistance.

SMRU honored at One Health Conference

On 13 August 2025, SMRU received the “One Health Champion” First Prize for its response to a cholera outbreak along the Thai–Myanmar border. Awarded at a national One Health conference, the recognition highlights SMRU’s excellence in cross-border disease surveillance and public health response through collaborative, sustainable policy efforts.

OUCRU and partners launch Kleb-CASAVA project

OUCRU and partners have officially launched the Klebsiella pneumoniae Community Acquired Infections Surveillance And Vaccine Development (Kleb-CASAVA) project. This collaborative initiative will strengthen surveillance of community-acquired Klebsiella pneumoniae infections and advance vaccine development to address the growing global threat of antimicrobial resistance

First volunteers receive Rift Valley fever vaccine in Kenya Phase II trial

On 8 July 2025, researchers at the KEMRI-Wellcome Trust Research Programme began the Phase II trial of the ChAdOx1 RVF vaccine in Kilifi, Kenya—the most advanced Rift Valley fever vaccine study in an outbreak-prone region. Led by Oxford University and funded by CEPI, this milestone brings us closer to a licensed vaccine for protecting lives and livelihoods.

Load More

Similar stories